YOU DO ALL YOU CAN TO TREAT YOUR PATIENTS’ PAIN EFFECTIVELY AND RESPONSIBLY. BUT PRESCRIBED OPIOID MEDICATIONS CAN FALL INTO THE WRONG HANDS IN THE COMMUNITY.

percentage1.jpg percentage2.jpg

In the 2015 National Survey on Drug Use and Health of people age 12 and older (N=68,073), 3,199 respondents (4.7%) reported misusing prescription pain relievers in the past year (~93% of which were opioids). When extrapolated to the U.S. population, an estimated 12.5 million Americans age 12 and older misused prescription pain relievers in the past year. Of those respondents who reported misusing pain relievers in the past year (n=3,199), 53.7% reported that they last obtained (given, bought, or took) them from a friend or relative.3

INJECTION AND INHALATION ARE PREVALENT ROUTES OF ER MORPHINE ABUSE.4

ROUTES OF ABUSE

routes_abuse_mobile.png

Data from 2009 Addiction Severity Index-Multimedia Version (ASI-MV®) Connect; an assessment of 59,792 patients entering treatment for substance use disorders at 464 treatment facilities in 34 states. 14.6% reported abusing at least one prescription opioid in the previous 30 days. Respondents could report more than one route of abuse in the previous 30 days.4

In 2016, 98.5% of prescribed ER morphine products were not abuse-deterrent formulations (ADFs).5 Non-ADF ER morphine products are easy to manipulate for abuse and misuse.

TREAT CHRONIC PAIN WITH ARYMO® ER (morphine sulfate) extended-release tablets CII

ARYMO ER with Guardian™ Technology is an abuse-deterrent formulation (ADF) of extended-release morphine sulfate. It is bioequivalent to MS Contin® (non-ADF).1

  • Available in 15, 30, and 60 mg dose strengths
  • Bioequivalent to MS Contin®1
  • Can be taken with or without food2
  • Taken orally every 8 or 12 hours2
  • A familiar molecule — morphine is the #1-prescribed extended-release opioid for the treatment of chronic pain6

Abuse of ARYMO ER by injection, as well as by oral and nasal routes, is still possible.

pills.png

POLYMER MATRIX + INJECTION MOLDING = GUARDIAN TECHNOLOGY
A FORMULA FOR RESISTING MANIPULATION

ARYMO ER with Guardian Technology combines a polymer matrix formulation with an injection molding manufacturing process. This unique coupling produces a tablet that is more difficult to manipulate physically and chemically than MS Contin.®2

  • Demonstrated increased resistance to manipulation (cutting, crushing, grinding, or breaking) and chemical extraction2
  • Has physical and chemical properties that are expected to make abuse via injection difficult2
  • Does not contain a sequestered antagonist such as naltrexone

Abuse of ARYMO ER by injection, as well as by oral and nasal routes, is still possible.

RESISTS PHYSICAL MANIPULATION

cutting

RESISTS CUTTING

crushing

RESISTS CRUSHING

grinding

RESISTS GRINDING

breaking

RESISTS BREAKING

syringeability

RESISTS SYRINGEABILITY

In vitro data demonstrate that in comparison with non-abuse-deterrent extended-release morphine sulfate tablets, ARYMO ER tablets have increased resistance to manipulation, eg, cutting, crushing, grinding, or breaking.2 It was observed that attempts to crush and grind ARYMO ER tablets resulted in damage to some mechanical and electrical household tools, including a mortar and pestle and a coffee grinder.7

Attempting to cut, break, chew, crush, or dissolve ARYMO ER tablets may compromise some of the extended-release properties, resulting in delivery of morphine that could lead to overdose and death.

See abuse deterrence studies